ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 770 USD | -0.15% |
|
+1.32% | +32.09% |
| 05-17 | Roche: share price stands out, Deutsche Bank in support | CF |
| 05-16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
| Sales 2024 * | 43B 3,386B | Sales 2025 * | 52.61B 4,143B | Capitalization | 693B 54,592B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 940B | Net income 2025 * | 16.55B 1,303B | EV / Sales 2024 * | 16.6 x |
| Net Debt 2024 * | 19.98B 1,573B | Net Debt 2025 * | 15.29B 1,204B | EV / Sales 2025 * | 13.5 x |
| P/E ratio 2024 * |
57.6
x | P/E ratio 2025 * |
41.4
x | Employees | 43,000 |
| Yield 2024 * |
0.68% | Yield 2025 * |
0.78% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.15% | ||
| 1 week | +1.32% | ||
| Current month | -1.42% | ||
| 1 month | +2.56% | ||
| 3 months | -1.54% | ||
| 6 months | +30.13% | ||
| Current year | +32.09% |
1 week
750.53
787.66
1 month
718.30795.50
Current year
579.05800.78
1 year
419.80800.78
3 years
193.11800.78
5 years
101.36800.78
10 years
58.22800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 31/12/00 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 17 M€ | +7.73% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 770 | -0.15% | 1,670,317 |
| 16/05/24 | 771.1 | -2.02% | 2,299,653 |
| 15/05/24 | 787 | +3.02% | 3,038,253 |
| 14/05/24 | 764 | +0.83% | 1,956,229 |
| 13/05/24 | 757.7 | -0.30% | 1,848,926 |
Delayed Quote Nyse, May 17, 2024 at 09:00 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B | |
| -0.52% | 162B |
- Stock Market
- Equities
- LLY Stock
